At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Mouth rinsedrug
Likely dose
Mouth rinse 10 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized Trial to Test the Effect of Povidone-iodine 0.5% as Mouthwash/Gargle on SARS-CoV-2 Load (COVID 19) as an Adjuvant Infection Control Measure in Dental Practice
In Brief
A Phase 2 clinical trial evaluating Mouth rinse for COVID-19. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals. Phase II is designed as an open label trial, and all subjects will receive the active mouthwash.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsAvrio Health
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartFeb 2022
First PostedFeb 2022
Primary CompletionJul 2022
Study CompletionJul 2022
TodayJul 2026
First PostedFeb 15, 2022
Enrollment StartFeb 7, 2022
Primary CompletionJul 7, 2022
Study CompletionJul 13, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.4 years ago
Interventions
Mouth rinsedrug
Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.